SecBot SecBot

EQ

Equillium, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001746466 Biotech & Drug Discovery
$1.25 +0.02 (+1.63%)
Oct 26 4:00 PM ET · prev $1.23
Market cap
$80.5M
Micro cap
Consensus
Buy
94% Buy or better · 18 analysts
Median target
$7.00
+460% · range $4.00–20.00
Next earnings
Nov 11
in 15 days
1 year
−8.8%
from $1.37 · Oct 27
30 days
−25.6%
from $1.68
52-week range
$0.8400–3.20
−61% from high · low Nov 13
Avg volume 20D
741.8K
Oct 19 spike 3.19M
Short interest
🔒 Subscribers only
Insider net
−$2.2M
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 1 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 2/5 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a Phase 1…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $2.2M.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    17 of 18 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    32% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM1,390,253$4.4M
BALYASNY ASSET MANAGEMENT L.P.NEAR_EXIT344,409$1.1M
TUDOR INVESTMENT CORP ET ALDOUBLED320,100$1.0M
BlackRock, Inc.DOUBLED285,409$913.3K
CITADEL ADVISORS LLCTRIM99,662$318.9K
JANE STREET GROUP, LLCTRIM95,214$304.7K
CITIGROUP INCDOUBLED32,695$104.6K
MORGAN STANLEYADD29,887$95.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +460%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 4, 2026Roth Capital
REITERATE
REITERATEBuy
Jul 13, 2026Piper Sandler
INITIATE
INITIATEOverweight
Jun 2, 2026Roth Capital
REITERATE
REITERATEBuy
May 28, 2026Leerink Partners
UPGRADE
UPGRADEOutperform
May 28, 2026Roth Capital
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$2.2M
sold · 3 insiders
DateInsiderTypeValue
Jun 5, 2026
Zedelmayer Christine
Sr. Vice President and COO
SELL$42.7K
Jun 5, 2026
Zedelmayer Christine
Sr. Vice President and COO
EXERCISE$11.4K
Jun 5, 2026
Connelly Stephen
President and CSO
SELL$91.1K
Jun 4, 2026
Connelly Stephen
President and CSO
SELL$632.8K
May 28, 2026
Zedelmayer Christine
Sr. Vice President and COO
SELL$90.0K
May 28, 2026
Zedelmayer Christine
Sr. Vice President and COO
EXERCISE$12.3K
May 28, 2026
Zedelmayer Christine
Sr. Vice President and COO
EXERCISE$11.4K
May 28, 2026
Zedelmayer Christine
Sr. Vice President and COO
SELL$542.00

Earnings setup

Estimates
Nov 11
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 FDA
🔒 Fresh data, subscribers only
Oct 5, 2026 SEC
Equillium received regulatory clearance from Australian authorities (HREC and TGA) to begin a Phase 1 clinical trial…
8-K — Impact 3/10
Oct 5, 2026 Press
Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a Phase 1 trial of…
Impact 4/10
Jun 30, 2026 Inst.
ADAGE CAPITAL PARTNERS GP, — TRIM
1,390,253 shares ($4.4M)
Jun 30, 2026 Inst.
BALYASNY ASSET MANAGEMENT L.P. — NEAR_EXIT
344,409 shares ($1.1M)
Jun 11, 2026 SEC
Three major passive institutions (Vanguard, State Street, Morgan Stanley) added to their Equillium positions during Q3…
INST-CLUSTER — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
EQ Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 26, 2026
FDA
🔒 Fresh data, subscribers only
Oct 5, 2026
FDA
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study…
Sep 29, 2026
FDA
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulation New preclinical data further…
Sep 16, 2026
Press release
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat…
Aug 14, 2026
Short interest
Short Interest: EQ up 2% to 5.5M shares
Settlement 2026-08-14 | Days to cover: 10.00 | ≈8.73% of shares outstanding (est.)

SecBot reports

8 filings · 5 press releases · 0 bullish · 2 bearish · 6 neutral
All EQ filing & press-release reports (13)